- Home
- NAMM vs MCRB Comparison
NAMM vs MCRB Comparison
Compare NAMM & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAMM | MCRB |
|---|---|---|
| Founded | 2024 | 2010 |
| Country | Cayman Islands | United States |
| Employees | 1500 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 71.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NAMM | MCRB |
|---|---|---|
| Price | $1.48 | $4.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 309.6K | 85.7K |
| Earning Date | 04-02-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | $76.84 | N/A |
| Revenue Next Year | $85.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $4.59 |
| 52 Week High | $7.42 | $29.98 |
Technical Indicators
Market Signals| Indicator | NAMM | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 38.43 |
| Support Level | $1.32 | $4.59 |
| Resistance Level | $1.76 | $9.53 |
| Average True Range (ATR) | 0.13 | 0.39 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 48.94 | 33.64 |
Price Performance
Historical ComparisonAbout NAMM Namib Minerals Ordinary Shares
Namib Minerals is a Pan-African multi-asset mining platform for precious and critical metals, particularly gold. The company is an established gold producer with an attractive portfolio of three gold mines in Zimbabwe, Africa. Its gold mines include How Mine, Mazowe Mine, and Redwing Mine. Its segments include the How Mine, the Mazowe Mine, and the Redwing Mine, and Others.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.